Sepsis - Facts and myths. Activated protein C: Obligatory in sepsis?;Aktiviertes Protein C: Bei Sepsis Obligat?

Anaesthesist

Volumn 52, Issue SUPPL. 1, 2003, Pages

  Max, M ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; DROTRECOGIN;

BRAIN HEMORRHAGE; CLINICAL TRIAL; ECONOMIC EVALUATION; HEALTH CARE COST; HUMAN; INTENSIVE CARE; REVIEW; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ACTIVATED PROTEIN C RESISTANCE; CLINICAL TRIALS; HUMANS; PROTEIN C; SEPSIS;

EID: 0345865275     PISSN: 00032417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00101-003-0592-x     Document Type: Review

References (21)

1. Abraham E, Reinhart K, Svoboda P et al. (2001) Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 29:2081-2089
2. Angus DC, Wax RS (2001) Epidemiology of sepsis: an update. Crit Care Med 29:S109-116
3. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome and associated costs of care. Crit Care Med 29:1303-1310
4. Annane D, Sébille V, Charpentier C et al. (2002) Effect of treatment with low doses of hydrocortisone on mortality in patients with septic shock. JAMA 288:862-871
5. Anti-infective Drugs Advisory Committee (2002) FDA brief ng document: drotrecogin alfa (activated).http://wwwfdagov/ohrms/dockets/ac/01/slides/ 3797b1_02_FDAbriefing doc
6. Berghe G van den, Wouters P, Weekers F et al. (2001) Inntensive insulin therapy in critically ill patients. New Engl J Med 345:1359-1367
7. Bernard GR, Vincent J-L, Laterre PF et al., the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. New Engl J Med 344:699-709
8. Cate H ten (2000) Pathophysiology of disseminated intravascular coagulation in sepsis. Crit Care Med 28:S9-S11
9. Eichacker PQ, Gerstenberger EP, Banks SM, Cui X, Natanson C (2002) A metaanalysis of ALI and ARDS trials testing low tidal volumes. Am J Respir Crit Care Med, online publication. Cited September 2003
10. Ely EW, Bernard GR, Vincent JL (2002) Activated protein C for severe sepsis. New Engl J Med 347:1035-1036
11. Esmon CT (2000) Introduction: are natural anticoagulants candidates for modulating the inflammatory response to endotoxin? Blood 95:1113-1116
12. Levi M (2000) Keep in contact: the role of the contact system In infection and sepsis. Crit Care Med 28:3765-3766
13. Mammen EF (1998) The haematological manifestations of sepsis. J Antimicrob Chemother 41:17-24
14. Manns BJ, Lee H, Doig CJ, Johnson D, Donaldson C (2002) An economic evaluation of activated protein C treatment for severe sepsis. New Engl J Med 347:993-1000
15. Members of the ACCP/SCCM Consensus Conference Committee (1992) American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864-874
16. Morris PE, Light RB, Garber GE (2002) Identifying patients with severe sepsis who should not be treated with drotrecogin alfa (activated). Am J Surg 184:195-245
17. Rivers E, Nguyen B, Havstad S et al., the Early Goal-Directed Therapy Collaborative Group (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. New Engl J Med 345:1368-1377
18. Siegel JP (2002) Assessing the use of activated protein C in the treatment of severe sepsis. New Engl J Med 347:1030-1034
19. Sollet JP, Garber GE (2002) Selecting patients with severe sepsis for drotrecogin alfa (activated) therapy. Am J Surg 184:115-185
20. Warren BL, Eid A, Singer P et al., Kyber Sept Trial Study Group (2001) Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286:1869-1878
21. Warren HS, Suffredini AF, Eichacker PQ, Munford RS (2002) Risks and benefits of activated protein C treatment for severe sepsis. New Engl J Med 347:1027-1030